	US 12,029,818 B2
	Lapatinib particles and uses thereof
Jacob Sittenauer, Lawrence, KS (US); Joseph Farthing, Lawrence, KS (US); Mark Williams, Lawrence, KS (US); Michael Baltezor, Lawrence, KS (US); Gere Dizerega, Lawrence, KS (US); Aranza Barreda Abarca, Lawrence, KS (US); and Shelby Clark, Lawrence, KS (US)
Assigned to CRITITECH, INC., Lawrence, KS (US)
Filed by CRITITECH, INC., Lawrence, KS (US)
Filed on Jul. 14, 2022, as Appl. No. 17/812,479.
Application 17/812,479 is a continuation of application No. 17/381,786, filed on Jul. 21, 2021, abandoned.
Claims priority of provisional application 63/055,788, filed on Jul. 23, 2020.
Prior Publication US 2022/0370355 A1, Nov. 24, 2022
Int. Cl. A61K 9/14 (2006.01); A61K 31/5365 (2006.01); A61K 47/26 (2006.01)

CPC A61K 9/14 (2013.01) [A61K 31/5365 (2013.01); A61K 47/26 (2013.01)]

17 Claims

1. A composition, comprising particles comprising at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 11 m²/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.